指南与共识脑血管病外科

欧洲未破裂脑动静脉畸形治疗共识会议(获EANS、ESMINT、EGKS与SINCH支持)

European consensus conference on unruptured brain AVMs treatment (Supported by EANS, ESMINT, EGKS, and SINCH).
指南 / 共识 · Acta Neurochir (Wien) · 2017-04-07

2016年12月,涉及EANS、ESMINT和EGKS三个欧洲学会24名成员的未破裂AVM治疗共识会议在意大利米兰召开。专家组就未破裂脑动静脉畸形的自然史、ARUBA试验结果适用性、多学科团队评估、Spetzler-Martin 1-2级治疗指征及高级别病例的个体化决策等提出声明和建议,并提议建立前瞻性欧洲多学科注册研究。

要点

  • 未破裂脑动静脉畸形患者应由神经外科、神经介入、放射外科及神经内科组成的多学科神经血管团队评估。
  • 权衡出血风险与治疗风险后,有充分指征治疗Spetzler-Martin 1级和2级未破裂AVM。
  • 更高级别患者可能基于经验丰富团队的个案共识决策存在治疗指征。

核心结论

  • 专家组认为脑动静脉畸形是复杂疾病且自然史可能严重,ARUBA随机试验结果不能同等适用于所有未破裂AVM和所有治疗方式。

研究设计与样本

  • 2016年12月在意大利米兰召开共识会议,由治疗脑AVM的三个欧洲学会(EANS、ESMINT和EGKS)的24名成员参与。

主要发现

  • 专家组提出7条声明和一般建议,涵盖疾病复杂性、ARUBA试验适用性、多学科团队评估、Spetzler-Martin 1-2级治疗指征、高级别个体化决策、治疗前多学科团队确定以完全根除为目标的策略,以及提议前瞻性欧洲多学科注册研究。

关键数值与推荐

  • 权衡未治疗未破裂AVM的出血风险及日常活动限制与治疗风险后,有充分指征治疗Spetzler-Martin 1级和2级未破裂AVM。
  • 更高级别患者可能基于经验丰富团队的个案共识决策存在治疗指征。
  • 若指示治疗,主要策略应由多学科团队在治疗开始前确定,并应以完全根除未破裂AVM为目标。
  • 患者应由包括神经外科医生、神经介入医生、放射外科医生和神经内科医生的跨学科神经血管团队评估。

临床怎么用

  • 未破裂脑AVM患者应由神经外科、神经介入、放射外科及神经内科组成的多学科神经血管团队评估。
  • Spetzler-Martin 1级和2级未破裂AVM有充分治疗指征。
  • 更高级别未破裂AVM的治疗指征可基于经验丰富团队的个案共识决策。
  • 若决定治疗,多学科团队应在治疗开始前确定以完全根除为目标的主要策略。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In December of 2016, a Consensus Conference on unruptured AVM treatment, involving 24 members of the three European societies dealing with the treatment of cerebral AVMs (EANS, ESMINT, and EGKS) was held in Milan, Italy. The panel made the following statements and general recommendations: (1) Brain arteriovenous malformation (AVM) is a complex disease associated with potentially severe natural history; (2) The results of a randomized trial (ARUBA) cannot be applied equally for all unruptured brain arteriovenous malformation (uBAVM) and for all treatment modalities; (3) Considering the multiple treatment modalities available, patients with uBAVMs should be evaluated by an interdisciplinary neurovascular team consisting of neurosurgeons, neurointerventionalists, radiosurgeons, and neurologists experienced in the diagnosis and treatment of brain AVM; (4) Balancing the risk of hemorrhage and the associated restrictions of everyday activities related to untreated unruptured AVMs against the risk of treatment, there are sufficient indications to treat unruptured AVMs grade 1 and 2 (Spetzler-Martin); (5) There may be indications for treating patients with higher grades, based on a case-to-case consensus decision of the experienced team; (6) If treatment is indicated, the primary strategy should be defined by the multidisciplinary team prior to the beginning of the treatment and should aim at complete eradication of the uBAVM; (7) After having considered the pros and cons of a randomized trial vs. a registry, the panel proposed a prospective European Multidisciplinary Registry.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Cenzato M, Boccardi E, Beghi E, et al. European consensus conference on unruptured brain AVMs treatment (Supported by EANS, ESMINT, EGKS, and SINCH). Acta Neurochir (Wien). 2017. PMID: 28389875. doi:10.1007/s00701-017-3154-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。